Taxonomy

Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A

Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A GLENOLDEN,

Diana Bharucha-Goebel, MD Joins the CMTA-STAR Advisory Board

In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA)

CMTA Appoints Katherine Forsey Chief Research Officer

(GLENOLDEN, Pa. – June 2, 2022) The Charcot-Marie-Tooth Association today

Data Shows Benefit with PXT3003 in Patients with CMT1A

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit

Orphan Drug Designation for TSHA-120 for Treatment of GAN

Taysha Gene Therapies Receives Orphan Drug Designation from the European

2021 STAR Accomplishments

With our community’s help, the CMTA has invested over $17.5

Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of

CMTA Seed Money Draws NIH Support For Type 2 Gene Editing

CMTA Seed Money Draws NIH Support For Type 2 Gene

CMTA-STAR Awards $354,826 for CMT Clinical Trial

CMTA-STAR Awards $354,826 for CMT Clinical Trial (Glenolden, PA, December

CMTA-STAR Awards Researcher $98,985 For CMT1A Project

CMTA-STAR Awards Researcher $98,985 For CMT1A Project Using Dental Pulp